JP2008502721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502721A5 JP2008502721A5 JP2007527522A JP2007527522A JP2008502721A5 JP 2008502721 A5 JP2008502721 A5 JP 2008502721A5 JP 2007527522 A JP2007527522 A JP 2007527522A JP 2007527522 A JP2007527522 A JP 2007527522A JP 2008502721 A5 JP2008502721 A5 JP 2008502721A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- compound according
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 carboxyl ester Chemical class 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229950006410 tezacitabine Drugs 0.000 claims 2
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 1
- 125000006334 2,4-difluoro benzoyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(F)C([H])=C1F 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 claims 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006291 3-hydroxybenzyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical compound NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- UYTKFWJKADWKBQ-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzyl-7-chloroquinolin-2-yl)-2-methylpropyl]-3-fluoro-4-methylbenzamide Chemical compound N=1C2=CC(Cl)=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C(F)=C1 UYTKFWJKADWKBQ-UHFFFAOYSA-N 0.000 claims 1
- TVEXKRMIKGLDGZ-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzyl-7-chloroquinolin-2-yl)-2-methylpropyl]-4-methylbenzamide Chemical compound N=1C2=CC(Cl)=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C=C1 TVEXKRMIKGLDGZ-UHFFFAOYSA-N 0.000 claims 1
- VUWDJNTXMFZAOD-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzylquinolin-2-yl)-2-methylpropyl]-3,4-dimethylbenzamide Chemical compound N=1C2=CC=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C(C)=C1 VUWDJNTXMFZAOD-UHFFFAOYSA-N 0.000 claims 1
- DQOAEPATSHONEH-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzylquinolin-2-yl)-2-methylpropyl]-3-fluoro-4-methylbenzamide Chemical compound N=1C2=CC=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C(F)=C1 DQOAEPATSHONEH-UHFFFAOYSA-N 0.000 claims 1
- KYRXWHYMQRFSMR-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzylquinolin-2-yl)-2-methylpropyl]-4-methylbenzamide Chemical compound N=1C2=CC=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C=C1 KYRXWHYMQRFSMR-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57312004P | 2004-05-21 | 2004-05-21 | |
| PCT/US2005/017961 WO2005113507A1 (en) | 2004-05-21 | 2005-05-19 | Substituted quinoline derivatives as mitotic kinesin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502721A JP2008502721A (ja) | 2008-01-31 |
| JP2008502721A5 true JP2008502721A5 (enExample) | 2008-06-19 |
Family
ID=34970815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527522A Pending JP2008502721A (ja) | 2004-05-21 | 2005-05-19 | 分裂キネシンインヒビターとしての置換キノリン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7452996B2 (enExample) |
| EP (1) | EP1753723B1 (enExample) |
| JP (1) | JP2008502721A (enExample) |
| CN (1) | CN1956960A (enExample) |
| AT (1) | ATE404536T1 (enExample) |
| AU (1) | AU2005245492A1 (enExample) |
| BR (1) | BRPI0511433A (enExample) |
| CA (1) | CA2564215A1 (enExample) |
| DE (1) | DE602005008953D1 (enExample) |
| DK (1) | DK1753723T3 (enExample) |
| ES (1) | ES2311992T3 (enExample) |
| HR (1) | HRP20080493T3 (enExample) |
| MX (1) | MXPA06011958A (enExample) |
| PL (1) | PL1753723T3 (enExample) |
| PT (1) | PT1753723E (enExample) |
| RS (1) | RS50670B (enExample) |
| RU (1) | RU2385867C2 (enExample) |
| SI (1) | SI1753723T1 (enExample) |
| WO (1) | WO2005113507A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0511433A (pt) * | 2004-05-21 | 2007-12-11 | Chiron Corp | derivados de quinolina substituìda como inibidores de cinesina mitótica |
| AU2005273705B8 (en) | 2004-08-18 | 2010-01-28 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP3095456A1 (en) * | 2005-11-04 | 2016-11-23 | Glaxosmithkline LLC | Methods for administering hypoglycemic agents |
| BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
| CA2668661A1 (en) * | 2006-11-13 | 2008-05-29 | Novartis Ag | Substituted pyrazole and triazole compounds as ksp inhibitors |
| MX2009007260A (es) * | 2007-01-05 | 2009-07-10 | Novartis Ag | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| US8748626B2 (en) * | 2010-04-15 | 2014-06-10 | Novartis Ag | Oxazole and thiazole compounds as KSP inhibitors |
| AU2011239977B2 (en) * | 2010-04-15 | 2014-11-27 | Novartis Ag | Triazole compounds as KSP inhibitors |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| US9458161B1 (en) | 2011-11-03 | 2016-10-04 | Vanderblit University | TSPO ligands for cancer imaging and treatment |
| NZ631362A (en) * | 2012-08-13 | 2016-09-30 | Array Biopharma Inc | Arry-520 for use in treating cancer in a patient with low aag |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| KR20250024102A (ko) | 2015-02-25 | 2025-02-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| RU2728932C2 (ru) * | 2015-08-19 | 2020-08-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения рака желчевыводящих путей |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US20200197384A1 (en) | 2017-05-16 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
| EP1165519A1 (en) | 1999-04-02 | 2002-01-02 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| DE60028227T2 (de) | 1999-10-27 | 2007-03-29 | Cytokinetics, Inc., South San Francisco | Chinazolinone benutzende verfahren und zusammenstellungen |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| AU2001296799A1 (en) | 2000-10-06 | 2002-04-15 | Neurogen Corporation | Benzimidazole and indole derivatives as crf receptor modulators |
| KR100883184B1 (ko) | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Ｃｘｃｒ3 길항제 |
| EP1351671A1 (en) | 2001-01-19 | 2003-10-15 | Cytokinetics, Inc. | Triphenylmethane kinesin inhibitors |
| EP1360180A1 (en) | 2001-01-19 | 2003-11-12 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| WO2003039460A2 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US6753428B2 (en) | 2001-11-20 | 2004-06-22 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| WO2003049527A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7244723B2 (en) | 2001-12-06 | 2007-07-17 | Merck & Co., Inc. | Substituted furopyrimidinones as a mitotic kinesin inhibitors |
| DE60222302T2 (de) | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
| EP1481077B1 (en) | 2001-12-06 | 2009-11-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| EP1551812B1 (en) | 2001-12-06 | 2009-03-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003059289A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| CA2475879A1 (en) | 2002-02-15 | 2003-08-28 | Cytokinetics, Inc. | Synthesis of quinazolinones |
| AU2003249597B2 (en) | 2002-03-08 | 2007-06-28 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| PL211300B1 (pl) | 2002-04-17 | 2012-05-31 | Cytokinetics Inc | Związek i kompozycja zawierająca ten związek |
| WO2003094839A2 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
| AU2003270015A1 (en) | 2002-05-09 | 2003-12-02 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1513820A4 (en) | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| EP1509507A4 (en) | 2002-05-23 | 2006-09-13 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| PL374190A1 (en) | 2002-06-14 | 2005-10-03 | Merck & Co, Inc. | Mitotic kinesin inhibitors |
| AU2003236527A1 (en) | 2002-06-14 | 2003-12-31 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1515949B1 (en) | 2002-06-14 | 2007-03-14 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2005537257A (ja) | 2002-07-08 | 2005-12-08 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン結合部位 |
| EP1539727B1 (en) | 2002-07-17 | 2009-02-18 | Cytokinetics, Inc. | Compounds, compositions, and methods for treating cellular proliferative diseases |
| EP1537089A4 (en) | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | CONNECTIONS, COMPOSITIONS AND PROCEDURES |
| EP1539180A4 (en) | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| JP2005539062A (ja) | 2002-09-13 | 2005-12-22 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| BRPI0511433A (pt) * | 2004-05-21 | 2007-12-11 | Chiron Corp | derivados de quinolina substituìda como inibidores de cinesina mitótica |
-
2005
- 2005-05-19 BR BRPI0511433-0A patent/BRPI0511433A/pt not_active IP Right Cessation
- 2005-05-19 RS RSP-2008/0534A patent/RS50670B/sr unknown
- 2005-05-19 PT PT05752901T patent/PT1753723E/pt unknown
- 2005-05-19 PL PL05752901T patent/PL1753723T3/pl unknown
- 2005-05-19 ES ES05752901T patent/ES2311992T3/es not_active Expired - Lifetime
- 2005-05-19 US US11/133,509 patent/US7452996B2/en not_active Expired - Fee Related
- 2005-05-19 JP JP2007527522A patent/JP2008502721A/ja active Pending
- 2005-05-19 SI SI200530384T patent/SI1753723T1/sl unknown
- 2005-05-19 CN CNA2005800164405A patent/CN1956960A/zh active Pending
- 2005-05-19 WO PCT/US2005/017961 patent/WO2005113507A1/en not_active Ceased
- 2005-05-19 DK DK05752901T patent/DK1753723T3/da active
- 2005-05-19 MX MXPA06011958A patent/MXPA06011958A/es active IP Right Grant
- 2005-05-19 HR HR20080493T patent/HRP20080493T3/xx unknown
- 2005-05-19 DE DE602005008953T patent/DE602005008953D1/de not_active Expired - Lifetime
- 2005-05-19 AU AU2005245492A patent/AU2005245492A1/en not_active Abandoned
- 2005-05-19 EP EP05752901A patent/EP1753723B1/en not_active Expired - Lifetime
- 2005-05-19 AT AT05752901T patent/ATE404536T1/de not_active IP Right Cessation
- 2005-05-19 RU RU2006145336/04A patent/RU2385867C2/ru not_active IP Right Cessation
- 2005-05-19 CA CA002564215A patent/CA2564215A1/en not_active Abandoned
-
2008
- 2008-09-30 US US12/242,360 patent/US20090028858A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008502721A5 (enExample) | ||
| JP2008517057A5 (enExample) | ||
| RU2006145336A (ru) | Замещенные производные хинолина, как ингибиторы митотического кинезина | |
| JP2011057693A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| JP2010090138A5 (enExample) | ||
| JP2010533205A5 (enExample) | ||
| JP2020504742A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP5852678B2 (ja) | 抗腫瘍剤の効果増強剤 | |
| CA2552050A1 (en) | Substituted heterocycles and the uses thereof | |
| JP2007518822A5 (enExample) | ||
| CA2493225A1 (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| JP2011526924A5 (enExample) | ||
| JP2002523502A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| JP2014065696A5 (enExample) | ||
| JP2005534623A5 (enExample) | ||
| TW201922251A (zh) | 抗癌劑 | |
| JP2009536191A5 (enExample) | ||
| JP2005511699A5 (enExample) | ||
| JP2011517697A5 (enExample) | ||
| JP2011507896A5 (enExample) | ||
| JP2008500999A5 (enExample) | ||
| JP2008514718A5 (enExample) |